The landscape of diabetes management is rapidly changing , with the emergence of dual GIP and GLP-1 receptor agonists. Both The Tirzepatide and Retatrutide represent significant advancements; Tirzepatid already https://fannieksvm579659.tkzblog.com/42660719/tirzepatide-retatrutide-a-new-metabolic-health-duo